Dr Reddy’s says German regulator makes 6 observations on its Duvvada unit
Dr. Reddy’s says a German regulator has made 6 major observations about its Duvvada drug making facility in Andhra Pradesh, sending shares down as much as 7.1%
Bengaluru/Mumbai: Dr. Reddy’s Laboratories said on Friday a German regulator has made six major observations about its Duvvada drug making facility in the southern Indian state of Andhra Pradesh, sending shares down as much as 7.1%.
Dr. Reddy’s, in an exchange filing, did not however elaborate on the observations, which typically refer to aspects of the production process that must be improved in order to gain regulatory approval for exports.
A company spokeswoman did not immediately respond to a request for details of the observations on Friday.
The products manufactured at the unit are not currently exported to the European Union, it said.
Germany and the United Kingdom contribute the most to Dr. Reddy’s revenue from Europe, which rose 28% to Rs208 crore ($32.57 million) in the June quarter. Reuters
- Biocon receives EIR from USFDA for its Bengaluru facility producing sterile
- Infosys to now focus on relentless execution, stability concerns addressed: Nandan Nilekani
- McDonald’s adopts eco-friendly cutlery in West and South India
- US investors seek Chanda Kochhar’s ouster from ICICI Bank
- LIC seeks govt nod to buy controlling stake in IDBI Bank
Editor's Picks »
- WhatsApp to offer 24-hour customer support for its payments services in India
- Vodafone-Idea merger may get delayed as DoT looking to raise fresh demand of Rs4,700 crore
- PM Modi says violence can never solve any problem
- Narendra Modi inaugurates Delhi Metro’s Mundka-Bahadurgarh section
- Heads of 11-state owned banks to appear before parliamentary panel on Tuesday